Skip to main content
Welcome
My Experience
Registration Rates
Important Dates
Searchable Agenda
Full Agenda
Preconference
Workshops
By Presenter
By Title
Posters
By Title
By Presenter
By Date
E-Posters
Login Required
Speaker Announcement
Hotel Information
Phoenix Dining & Attractions
Workshop/Tutorial Descriptions
Virtual Exhibit Hall
Future ACoP Meetings
Exhibit Application Info
Year Round Sponsorship Info
Toggle navigation
Login
Search
Home
Welcome
My Experience
Registration Rates
Important Dates
+
Searchable Agenda
Full Agenda
Preconference
Workshops
By Presenter
By Title
+
Posters
By Title
By Presenter
By Date
E-Posters
Login Required
Speaker Announcement
Hotel Information
Phoenix Dining & Attractions
Workshop/Tutorial Descriptions
Virtual Exhibit Hall
Future ACoP Meetings
Exhibit Application Info
Year Round Sponsorship Info
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
18 results found
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Z
Zahir, Hamim
(
T-136
)
Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Hamim Zahir
Favorite
Zhang, Lily
Fred Hutch cancer center
(
W-140
)
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
Lily Zhang
Favorite
Zhang, Sihong
University of North Carolina at Chapel Hill
(
T-138
)
Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials
Sihong Zhang
Favorite
Zhang, Xianwei
Alnylam Pharmaceuticals
(
M-134
)
A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor
Xianwei Zhang
Favorite
Zhang, Xinwen
Clinical Pharmacology Modeling & Simulation, Amgen
(
T-137
)
Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients
Xinwen Zhang
Favorite
Zhang, Yi
Critical Path Institute
(
M-135
)
A Bayesian disease progression model for Major Depressive Disorder
Yi Zhang
Favorite
(
M-136
)
A time-to-event model for Bronchopulmonary dysplasia based on real-world data
Yi Zhang
Favorite
Zhao, Janet
Certara Inc.
(
M-137
)
A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Janet Zhao
Favorite
Zhao, Molly
(
W-083
)
Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Molly Zhao
Favorite
Zhao, Yuan
EMD Serono, Billerica, MA, USA
(
W-141
)
Disease progression modeling of myositis from real-world data
Yuan Zhao
Favorite
Zheng, Fudan
Johnson & Johnson Innovative Medicine
(
T-139
)
Population Pharmacokinetics and Exposure-response Analyses of Amivantamab Administered in Combination with Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Fudan Zheng
Favorite
Zheng, Xirong
Bristol Myers Squibb
(
M-138
)
Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Xirong Zheng
Favorite
(
M-139
)
Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma
Xirong Zheng
Favorite
Zhong, Rui
University of North Carolina at Chapel Hill
(
T-140
)
Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy
Rui Zhong
Favorite
Zhou, Jessie
Johnson and Johnson
(
M-140
)
Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
Jessie Zhou
Favorite
Zhou, Jia
Janssen Research & Development, LLC, Spring House, PA, USA
(
T-141
)
Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
Jia Zhou
Favorite
Zhou, Jiawei
Pfizer, Inc.
(
M-141
)
Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration
Jiawei Zhou
Favorite
Zhu, Rui
Genentech
(
M-142
)
Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988
Rui Zhu
Favorite
Back to Top
